Resonance Health Akcie

Resonance Health EBITDA

EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) společnosti Resonance Health (RHT.AX) k datu 14. 8. 2026 je -875 300,00 AUD. V předchozím roce byl EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) -167 300,00 AUD — změna o 423,19 % (nižší).

EBITDA

-875 300,00AUD

YoY

423,19%

Poslední aktualizace:

EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) společnosti Resonance Health je 2026 -875 300,00 AUD. EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) společnosti Resonance Health byl 2025 -167 300,00 AUD. Klesá tak o 423,19% nižší než v předchozím roce.
Access this data via the Eulerpool API

Resonance Health Analýza akcií

Co dělá Resonance Health? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií Resonance Health

EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) společnosti Resonance Health činí -875 300,00 AUD v roce 2026.

EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) společnosti Resonance Health se změnilo z -167 300,00 AUD na -875 300,00 AUD, což představuje změnu o 423,19 %. Hodnota je nižší než v předchozím roce.

Na Eulerpool najdete úplný historický vývoj EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) Resonance Health od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

EBITDA měří operační výkonnost před dopadem finanční struktury, daňového prostředí a bezhotovostních odpisů.

EBITDA = EBIT + Odpisy

AUD společnosti EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) je důležitým faktorem pro investory. Změny v tomto ukazateli mohou signalizovat zlepšování nebo zhoršování fundamentů, což může ovlivnit cenu akcie. Na Eulerpool můžete sledovat Resonance Health společnosti EBITDA (Zisk před úroky, daněmi, odpisy a amortizací) historicky.

Access this data via the Eulerpool API

Výkaz zisku a ztráty — Resonance Health

Všechny klíčové ukazatele — Resonance Health